These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 10825607)

  • 1. Local and systemic immune responses to combined vibrio cholerae CVD103-HgR and salmonella typhi ty21a live oral vaccines after primary immunization and reimmunization.
    Kollaritsch H; Cryz SJ; Lang AB; Herzog C; Que JU; Wiedermann G
    Vaccine; 2000 Jul; 18(26):3031-9. PubMed ID: 10825607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of live oral cholera and typhoid vaccines administered alone or in combination with antimalarial drugs, oral polio vaccine, or yellow fever vaccine.
    Kollaritsch H; Que JU; Kunz C; Wiedermann G; Herzog C; Cryz SJ
    J Infect Dis; 1997 Apr; 175(4):871-5. PubMed ID: 9086143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.
    Kollaritsch H; Furer E; Herzog C; Wiedermann G; Que JU; Cryz SJ
    Infect Immun; 1996 Apr; 64(4):1454-7. PubMed ID: 8606118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria.
    Viret JF; Favre D; Wegmüller B; Herzog C; Que JU; Cryz SJ; Lang AB
    Infect Immun; 1999 Jul; 67(7):3680-5. PubMed ID: 10377160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.
    Cryz SJ; Que JU; Levine MM; Wiedermann G; Kollaritsch H
    Infect Immun; 1995 Apr; 63(4):1336-9. PubMed ID: 7890391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo evidence of immunological masking of the Vibrio cholerae O antigen of a hybrid Salmonella typhi Ty21a-Vibrio cholerae oral vaccine in humans.
    Forrest BD; LaBrooy JT
    Vaccine; 1991 Jul; 9(7):515-20. PubMed ID: 1716810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral immunization with Salmonella typhi Ty21a-based clones expressing Vibrio cholerae O-antigen: serum bactericidal antibody responses in man in relation to pre-immunization antibody levels.
    Attridge S
    Vaccine; 1991 Dec; 9(12):877-82. PubMed ID: 1725837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a.
    Tacket CO; Forrest B; Morona R; Attridge SR; LaBrooy J; Tall BD; Reymann M; Rowley D; Levine MM
    Infect Immun; 1990 Jun; 58(6):1620-7. PubMed ID: 1692807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans.
    Wahid R; Simon R; Zafar SJ; Levine MM; Sztein MB
    Clin Vaccine Immunol; 2012 Jun; 19(6):825-34. PubMed ID: 22492745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalent cholera and typhoid vaccine.
    Foster RH; Noble S
    Drugs; 1999 Jul; 58(1):91-6; discussion 97-8. PubMed ID: 10439932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine.
    Cancellieri V; Fara GM
    J Infect Dis; 1985 Mar; 151(3):482-4. PubMed ID: 3882850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Live Attenuated Cholera Vaccine CVD 103-HgR Primes Responses to the Toxin-Coregulated Pilus Antigen TcpA in Subjects Challenged with Wild-Type Vibrio cholerae.
    Mayo-Smith LM; Simon JK; Chen WH; Haney D; Lock M; Lyon CE; Calderwood SB; Kirkpatrick BD; Cohen M; Levine MM; Gurwith M; Harris JB
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with registered mucosal vaccines.
    Dietrich G; Griot-Wenk M; Metcalfe IC; Lang AB; Viret JF
    Vaccine; 2003 Jan; 21(7-8):678-83. PubMed ID: 12531339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and immunogenicity of EX880, a Salmonella typhi Ty21a-based clone which produces Vibrio cholerae O antigen.
    Attridge SR; Dearlove C; Beyer L; van den Bosch L; Howles A; Hackett J; Morona R; LaBrooy J; Rowley D
    Infect Immun; 1991 Jul; 59(7):2279-84. PubMed ID: 1711014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
    Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
    Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of humoral and protective immune response induced by live-attenuated Salmonella typhi by ampicillin.
    Woo PC; Tsoi HW; Leung HC; Yuen KY
    APMIS; 2000 May; 108(5):343-8. PubMed ID: 10937771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali.
    Perry RT; Plowe CV; Koumaré B; Bougoudogo F; Kotloff KL; Losonsky GA; Wasserman SS; Levine MM
    Bull World Health Organ; 1998; 76(1):63-71. PubMed ID: 9615498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
    Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
    Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers.
    Metzger WG; Mansouri E; Kronawitter M; Diescher S; Soerensen M; Hurwitz R; Bumann D; Aebischer T; Von Specht BU; Meyer TF
    Vaccine; 2004 Jun; 22(17-18):2273-7. PubMed ID: 15149786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.